For more than 70 years, the drug 6-thioguanine (6-TG) has been used to treat leukemia. Although its clinical effects have been studied extensively, scientists are still uncovering the molecular ...

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug ...

The use of nanoparticles in drug delivery offers key advantages: they can enable targeted drug delivery, protect active ingredients from premature degradation, extend their duration of action in the ...

Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts ...

Researchers identify a first-in-kind metabolically activated degrader that hints at a new class of protein-degrading drugs ...

A scalable platform to discover molecular glue degraders has been developed, identifying the first metabolically activated ...

From COVID-19 vaccines to Moderna’s mRNA flu vaccine, using mRNA as medicine has shown promise. But before mRNA drugs can go ...

Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that ...

Setidegrasib, a first-in-class KRAS G12D degrader, uses the cell’s own recycling system to destroy a key cancer driver ...

In a single news cycle, Pathos AI announced two simultaneous drug licensing agreements worth up to $2.3 billion in combined milestones — and disclosed that it is targeting a $300 million Series E ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter 2026, ...

ETH Zurich researchers developed light-controlled molecules that remove glucocorticoid receptors, waking dormant cancer cells ...